BR112017026294A2 - formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição. - Google Patents

formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.

Info

Publication number
BR112017026294A2
BR112017026294A2 BR112017026294A BR112017026294A BR112017026294A2 BR 112017026294 A2 BR112017026294 A2 BR 112017026294A2 BR 112017026294 A BR112017026294 A BR 112017026294A BR 112017026294 A BR112017026294 A BR 112017026294A BR 112017026294 A2 BR112017026294 A2 BR 112017026294A2
Authority
BR
Brazil
Prior art keywords
gel formulation
preventing
treating
disease
condition
Prior art date
Application number
BR112017026294A
Other languages
English (en)
Inventor
T Moore Anne
N Ringhoff Danielle
Lee Feiss Gary
M Mahoney Linda
Original Assignee
Dermarc LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermarc LLC filed Critical Dermarc LLC
Publication of BR112017026294A2 publication Critical patent/BR112017026294A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

esta invenção se refere a uma composição tópica para prevenção e tratamento de infecções virais. a presente invenção provê uma formulação em gel tópica farmacêutica que compreende: pelo menos composto antiviral, alquileno glicol, etanol, pelo menos um espessante, um tampão, água e opcionalmente, polialquileno glicol. a presente invenção provê uma formulação em gel tópica farmacêutica em que a formulação em gel tópica tem capacidade para entrega dérmica e/ou cutânea.
BR112017026294A 2015-06-08 2016-06-02 formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição. BR112017026294A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172463P 2015-06-08 2015-06-08
PCT/US2016/035443 WO2016200672A1 (en) 2015-06-08 2016-06-02 Therapeutic composition

Publications (1)

Publication Number Publication Date
BR112017026294A2 true BR112017026294A2 (pt) 2018-09-18

Family

ID=57450776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026294A BR112017026294A2 (pt) 2015-06-08 2016-06-02 formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.

Country Status (8)

Country Link
US (3) US9782426B2 (pt)
EP (1) EP3302439A4 (pt)
JP (1) JP2018522844A (pt)
CN (1) CN108348469A (pt)
BR (1) BR112017026294A2 (pt)
CA (1) CA2987132A1 (pt)
MX (1) MX2017015670A (pt)
WO (1) WO2016200672A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907751B2 (en) * 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US20190381178A1 (en) * 2017-03-02 2019-12-19 Duke University Methods for the treatment of cancer and benign lesions by ablation
IL285232B (en) * 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Preparations containing oleandrin for the treatment of viral infection
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
WO2019136196A1 (en) * 2018-01-08 2019-07-11 Dermarc LLC Therapeutic composition
FR3077984B1 (fr) * 2018-02-16 2020-02-21 Vetoquinol Sa Composition multiusage de torasemide
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2021163648A2 (en) * 2020-02-14 2021-08-19 Dyve Biosciences, Inc. Topical delivery of buffering agents for prevention and treatment of viral infections
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
RU2747987C1 (ru) * 2020-10-07 2021-05-18 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Композиция для лечения латентной и субклинической папилломавирусной инфекции шейки матки и способ ее применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US20040043946A1 (en) 2002-09-03 2004-03-04 Popp Karl F. Topical formulations for treatment of skin disorders
PT1670433E (pt) * 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
GB0517840D0 (en) * 2005-09-02 2005-10-12 Henderson Morley Plc Topical anti viral formulations
WO2009103932A1 (en) * 2008-02-19 2009-08-27 Henderson Morley Plc Use of a cardiac glycoside and/or a diuretic for the treatment of neuropathic pain

Also Published As

Publication number Publication date
MX2017015670A (es) 2018-08-15
EP3302439A4 (en) 2018-12-26
JP2018522844A (ja) 2018-08-16
EP3302439A1 (en) 2018-04-11
US20170000813A1 (en) 2017-01-05
US20170000814A1 (en) 2017-01-05
US10137140B2 (en) 2018-11-27
CA2987132A1 (en) 2016-12-15
US10130648B2 (en) 2018-11-20
WO2016200672A1 (en) 2016-12-15
CN108348469A (zh) 2018-07-31
US9782426B2 (en) 2017-10-10
US20160354396A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
DOP2019000117A (es) Nuevos derivados de quinolina
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
BR112015026830A2 (pt) composto, composição farmacêutica, uso de um composto, método para profilaxia ou tratamento de um estado de doença ou condição
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
UY37789A (es) Nuevos derivados de azaquinolina
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
DOP2016000253A (es) Nuevos compuestos
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
BR112022008365A2 (pt) Inibidores de cd73
CO2020013876A2 (es) Nuevos derivados de quinolina
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015026388A8 (pt) uso de um composto de epoxi-tigliane, composto e composição farmacêutica
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: MARUHO CO. LTD. (JP)

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements